Cancer Solid Tumors clinical trials

Explore recruiting cancer solid tumors clinical trials.

Recruiting cancer solid tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cancer Solid Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Dose escalation/expansion trial with BYON4228 alone and in combination in metastatic solid tumors

Spain, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)

Spain, Belgium, Sweden, Germany, Denmark, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).

France, Germany, Belgium, Austria, Spain, Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)

Sweden, France, Spain, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer

Italy, Netherlands, Belgium, Spain, Czechia, France +1 more

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab)

Netherlands, Germany, France, Spain, Hungary, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

Cancer Solid Tumors trials by city

Cancer Solid Tumors in Toronto Cancer Solid Tumors in Vancouver Cancer Solid Tumors in Montreal Cancer Solid Tumors in Calgary Cancer Solid Tumors in Edmonton Cancer Solid Tumors in Ottawa Cancer Solid Tumors in Winnipeg Cancer Solid Tumors in Quebec City Cancer Solid Tumors in Hamilton Cancer Solid Tumors in Kitchener Cancer Solid Tumors in London Cancer Solid Tumors in Halifax Cancer Solid Tumors in New York Cancer Solid Tumors in Los Angeles Cancer Solid Tumors in Chicago Cancer Solid Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease